Faricimab, Roche’s investigational bispecific antibody for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), has now been filed with the European Medicines Agency for review for potential pan-EU marketing authorization.
If approved, faricimab could become the first in a new class of medicine in 15 years for nAMD and in close to a decade for DME, according to Roche
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?